Skip to main content

2 posts tagged with "MSD"

View All Tags

Legit.Health honored by pharmaceutical giant MSD at the European Patient Digital Health Awards

· 5 min read
Andy Anguilar
CEO at Legit.Health
Alfonso Medela
CAIO at Legit.Health

The ceremony attended by European technology executives aims to promote digital innovation.

Legit.Health awarded at the European Patient Digital Health Awards 2021 by MSD

The European Patient Digital Health Awards (PDHA) ceremony, orchestrated by MSD — known for their innovation in COVID-19 treatment —, recently honored Legit.Health for its groundbreaking work in healthcare technology. Marking a significant milestone, Legit.Health is celebrated as the first Spanish company to clinch the PDHA award, a testament to its commitment to transforming patient care through digital innovation.

Aptar Digital Health and Legit.Health Partner to Improve Patient Experience in Immuno-Dermatology

· 4 min read
Andy Anguilar
CEO at Legit.Health
Alfonso Medela
CAIO at Legit.Health

This collaboration will integrate Legit.Health's innovative technology into Aptar Digital Health's proprietary digital health platform to better manage and treat skin conditions

Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, today announced a new partnership with Legit.Health, an innovative artificial intelligence (AI)-based medical device (CE-marked) software company, which aims to transform patient care and increase patient adherence to better manage skin conditions.

Legit.Health's state-of-the-art technology, which supports the diagnosis of approximately 300 conditions, including atopic dermatitis, psoriasis and skin cancer, will be integrated into Aptar's Digital Health proprietary platform. Focused on enhancing patient care and increasing patient autonomy, this advanced digital solution will support healthcare professionals (HCPs) to diagnose skin conditions earlier and will enable patients to start sooner on treatment plans to improve their overall quality of life. The solution may also be used to facilitate patient enrolment in clinical trials.